Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study - determination of immunogenicity.
作者信息
Warnock David G, Wallace Eric L
机构信息
Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA
Department of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
出版信息
J Med Genet. 2024 May 21;61(6):534-535. doi: 10.1136/jmg-2024-109876.
Abstract
摘要
相似文献
1
Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study - determination of immunogenicity.
J Med Genet. 2024 May 21;61(6):534-535. doi: 10.1136/jmg-2024-109876.
2
Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study-determination of immunogenicity.
J Med Genet. 2024 May 21;61(6):531-533. doi: 10.1136/jmg-2023-109818.
3
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
J Med Genet. 2024 May 21;61(6):520-530. doi: 10.1136/jmg-2023-109445.
4
Fabry disease, enzyme replacement therapy and the significance of antibody responses.
J Inherit Metab Dis. 2012 Mar;35(2):227-43. doi: 10.1007/s10545-011-9400-y. Epub 2011 Oct 25.
5
Agalsidase alfa: a review of its use in the management of Fabry disease.
BioDrugs. 2012 Oct 1;26(5):335-54. doi: 10.2165/11209690-000000000-00000.
6
Letter concerning "Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha", by Tanaka et al.
J Inherit Metab Dis. 2011 Feb;34(1):237-8. doi: 10.1007/s10545-010-9219-y. Epub 2010 Oct 12.
7
The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
Expert Opin Biol Ther. 2009 May;9(5):631-9. doi: 10.1517/14712590902902296.
8
Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
J Inherit Metab Dis. 2003;26(7):617-27. doi: 10.1023/b:boli.0000005658.14563.77.
9
Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
Mol Genet Metab. 2019 Apr;126(4):448-459. doi: 10.1016/j.ymgme.2019.02.005. Epub 2019 Feb 20.
10
Update on role of agalsidase alfa in management of Fabry disease.
Drug Des Devel Ther. 2011 Mar 14;5:155-73. doi: 10.2147/DDDT.S11985.
本文引用的文献
1
Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study-determination of immunogenicity.
J Med Genet. 2024 May 21;61(6):531-533. doi: 10.1136/jmg-2023-109818.
2
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
J Med Genet. 2024 May 21;61(6):520-530. doi: 10.1136/jmg-2023-109445.
3
Antibodies against recombinant enzyme in the treatment of Fabry disease: Now you see them, now you don't.
Mol Ther Methods Clin Dev. 2022 Oct 29;27:324-326. doi: 10.1016/j.omtm.2022.10.007. eCollection 2022 Dec 8.
4
Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfa.
Mol Ther Methods Clin Dev. 2022 Jul 31;26:323-330. doi: 10.1016/j.omtm.2022.07.009. eCollection 2022 Sep 8.
5
Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial.
J Inherit Metab Dis. 2019 May;42(3):534-544. doi: 10.1002/jimd.12080. Epub 2019 Apr 8.
6
Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease.
Mol Genet Metab. 2015 Feb;114(2):259-67. doi: 10.1016/j.ymgme.2014.08.002. Epub 2014 Aug 10.
Zotero 插件